Given the above lines of evidence, we conducted a clinical trial of MWA combined with apatinib [a vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor (TKI)] and camrelizumab (an anti-PD-1 monoclonal antibody) for the treatment of advanced HCC patients and evaluated the safety and efficacy of the combination treatment. The gene discussed is KDR; the disease is hepatocellular carcinoma.